Top Page
Alterity Therapeutics
(Sydney:ATH)
Alterity Therapeutics (ATH) vs. iShares MSCI Australia ETF (EWA)
Alterity Therapeutics Business Overview & Revenue Model
Alterity Therapeutics Financial Statement Overview
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.02M | 3.92M | 5.12M | 4.34M | 0.00 |
| Gross Profit | 3.80M | 3.63M | 4.76M | 3.98M | -112.43K |
| EBITDA | -19.57M | -17.51M | -17.39M | -19.36M | -13.34M |
| Net Income | -19.12M | -13.81M | -12.85M | -15.31M | -9.70M |
Balance Sheet | |||||
| Total Assets | 19.22M | 27.32M | 41.36M | 33.59M | 13.30M |
| Cash, Cash Equivalents and Short-Term Investments | 12.64M | 15.77M | 34.81M | 28.12M | 9.20M |
| Total Debt | 159.04K | 210.38K | 117.49K | 65.65K | 33.75K |
| Total Liabilities | 5.43M | 4.50M | 5.89M | 3.12M | 2.76M |
| Stockholders Equity | 13.80M | 22.81M | 35.47M | 30.47M | 10.55M |
Cash Flow | |||||
| Free Cash Flow | -12.61M | -20.04M | -12.43M | -17.34M | -9.45M |
| Operating Cash Flow | -12.61M | -20.04M | -12.34M | -17.33M | -9.43M |
| Investing Cash Flow | -5.72K | -36.46K | -89.15K | -10.47K | -16.74K |
| Financing Cash Flow | 9.22M | 124.34K | 16.30M | 36.69M | 3.98M |
Alterity Therapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | AU$102.84M | 10.60 | 45.86% | 1.83% | 71.65% | 152.89% | |
65 Neutral | ¥354.29B | 10.98 | -2.99% | 2.48% | 11.72% | -10.32% | |
55 Neutral | AU$112.78M | ― | ― | ― | -33.01% | ||
52 Neutral | $147.32M | ― | -154.88% | ― | ― | 20.00% | |
40 Underperform | $85.11M | ― | -99.05% | ― | ― | -33.99% | |
40 Underperform | $158.97M | ― | -46.65% | ― | 96.20% | 80.90% | |
40 Underperform | AU$124.80M | ― | -85.35% | ― | 315.11% | 51.16% |
Alterity Therapeutics Corporate Events
Alterity Therapeutics has released a corporate presentation that includes forward-looking statements. These statements, as per US Securities Laws, involve risks and uncertainties that could cause actual results to differ materially from expectations, highlighting the importance of understanding the associated risk factors.
Alterity Therapeutics has received U.S. FDA Fast Track Designation for its investigational drug ATH434, aimed at treating Multiple System Atrophy (MSA), a neurodegenerative disease with no approved therapies. This designation, along with positive results from Phase 2 clinical trials, highlights the potential of ATH434 to slow disease progression and improve symptoms, reinforcing the company’s confidence in its MSA program as it prepares for further interactions with the FDA.
Alterity Therapeutics announced positive topline results from its open-label Phase 2 clinical trial of ATH434 in patients with multiple system atrophy (MSA). The trial demonstrated that ATH434 provides clinical benefits by stabilizing neurological symptoms and slowing brain atrophy, with a favorable safety profile. These findings are consistent with previous studies and support the advancement of ATH434 as a potential treatment for MSA, a disease currently lacking modifying medications. The results are promising for stakeholders, indicating potential progress in addressing this challenging condition.
Alterity Therapeutics has announced the publication of a novel MRI endpoint from its bioMUSE Natural History Study in the Annals of Clinical and Translational Neurology. This publication highlights the development of the MSA Atrophy Index, a new neuroimaging measure that uses deep learning to track disease progression in Multiple System Atrophy (MSA) patients. The MSA-AI offers a standardized metric for assessing brain atrophy, which can aid in early diagnosis and improve clinical trial participant selection. The study’s findings underscore the potential of advanced neuroimaging methods to enhance understanding of MSA progression and support the evaluation of disease-modifying therapies.
Alterity Therapeutics Limited has announced the quotation of 95,238 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of July 16, 2025. This move is part of the company’s strategy to enhance its financial flexibility and support its ongoing research and development initiatives, potentially strengthening its position in the biotech sector and providing value to its stakeholders.
Alterity Therapeutics Limited announced the quotation of 79,999,800 fully paid ordinary securities on the Australian Securities Exchange (ASX) as of July 17, 2025. This move is likely to enhance the company’s financial flexibility and market presence, potentially impacting its strategic operations and offering new opportunities for stakeholders.
Alterity Therapeutics Limited has responded to a price query from the ASX regarding a recent increase in its share price and trading volume. The company stated it is unaware of any undisclosed information that could explain the trading activity. However, it highlighted upcoming data releases from its Phase 2 studies and an investor roadshow as potential factors influencing market anticipation.
Alterity Therapeutics Limited announced the issuance of 15 million unlisted options set to expire in July 2030, as part of an employee incentive scheme. This move is likely to enhance employee engagement and retention, potentially strengthening the company’s operational capabilities and competitive positioning in the biotechnology sector.
Alterity Therapeutics announced that its CEO, David Stamler, will provide a corporate update during a Fireside Chat hosted by MST Access, focusing on the progress of the ATH434 development program for Multiple System Atrophy. This announcement follows the positive Phase 2 data released in January, highlighting the company’s ongoing efforts to advance its clinical trials and strengthen its position in the biotechnology industry, potentially impacting stakeholders and the market for neurodegenerative disease treatments.
The Bank of New York Mellon Corporation (BNYMC) has increased its substantial holding in Alterity Therapeutics Limited, now holding a 27.03% voting power compared to the previous 26.01%. This change indicates a growing interest and confidence in Alterity’s operations, potentially impacting the company’s market positioning and stakeholder relations.
Alterity Therapeutics announced significant findings from its clinical programs at the 2025 International MSA Congress, highlighting the efficacy of its ATH434 treatment in reducing disease severity and improving symptoms in MSA patients. The introduction of the MSA Atrophy Index as a diagnostic and monitoring tool, along with insights from the bioMUSE study, underscores Alterity’s commitment to advancing MSA treatment and enhancing diagnostic capabilities, potentially impacting patient care and clinical practices.
The Bank of New York Mellon Corporation (BNYMC) has increased its voting power in Alterity Therapeutics Limited from 24.95% to 26.01%, as of May 8, 2025. This change in substantial holding indicates a strengthened position for BNYMC in the company, potentially impacting Alterity’s strategic decisions and shareholder dynamics.
Alterity Therapeutics announced its participation in the 2025 International MSA Congress, where it will present multiple oral and poster presentations on its clinical programs for Multiple System Atrophy (MSA). The presentations will highlight the Phase 2 data for ATH434, which has shown significant clinical efficacy and safety in treating MSA. The company’s involvement in the congress underscores its commitment to advancing MSA research and care, further supported by the recent Fast Track Designation for ATH434 by the US FDA.
Alterity Therapeutics announced that the U.S. FDA has granted Fast Track designation for its lead candidate, ATH434, aimed at treating Multiple System Atrophy (MSA). This designation is expected to accelerate the development and review process of ATH434, highlighting its potential to meet the high unmet need for MSA treatments. The Fast Track status allows Alterity to engage more frequently with the FDA, potentially speeding up the path to approval. The company has demonstrated ATH434’s efficacy and safety in Phase 2 trials, showing significant improvements in clinical outcomes for MSA patients.